NO20063676L - Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer - Google Patents

Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer

Info

Publication number: NO20063676L
Authority: NO; Norway
Prior art keywords: inhibitors; indole derivatives; kinase inhibitors; particular ikk2; kinase
Prior art date: 2004-01-15

Application number

NO20063676A

Other languages

English (en)

Norwegian (no)

Inventor

Paul Bamborough

Lan Robert Baldwin

John Andrew Christopher

Jeffrey K Kerns

Timothy Longstaff

David Drysdale Miller

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-15

Filing date

2006-08-15

Publication date

2006-10-13

2006-08-15 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2006-10-13 Publication of NO20063676L publication Critical patent/NO20063676L/no

Links

102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 title abstract 2
101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
229940054051 antipsychotic indole derivative Drugs 0.000 title 1
150000002475 indoles Chemical class 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
230000000694 effects Effects 0.000 abstract 2
VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
230000017423 tissue regeneration Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)

NO20063676A 2004-01-15 2006-08-15 Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer NO20063676L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0400895.9A GB0400895D0 (en)	2004-01-15	2004-01-15	Chemical compounds
PCT/GB2005/000085 WO2005067923A1 (en)	2004-01-15	2005-01-13	Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors

Publications (1)

Publication Number	Publication Date
NO20063676L true NO20063676L (no)	2006-10-13

Family

ID=31726240

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20063676A NO20063676L (no)	2004-01-15	2006-08-15	Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer

Country Status (23)

Country	Link
US (1)	US20080269200A1 (de)
EP (1)	EP1703905B1 (de)
JP (2)	JP4975447B2 (de)
KR (1)	KR20070026357A (de)
CN (1)	CN1933830A (de)
AT (1)	ATE413877T1 (de)
AU (1)	AU2005205090A1 (de)
BR (1)	BRPI0506802A (de)
CA (1)	CA2552953A1 (de)
DE (1)	DE602005010970D1 (de)
DK (1)	DK1703905T3 (de)
ES (1)	ES2317184T3 (de)
GB (1)	GB0400895D0 (de)
HR (1)	HRP20090071T3 (de)
IL (1)	IL176739A0 (de)
MA (1)	MA28279A1 (de)
NO (1)	NO20063676L (de)
PL (1)	PL1703905T3 (de)
PT (1)	PT1703905E (de)
RU (1)	RU2006129492A (de)
SI (1)	SI1703905T1 (de)
WO (1)	WO2005067923A1 (de)
ZA (1)	ZA200604855B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200616967A (en) *	2004-06-24	2006-06-01	Smithkline Beecham Corp	Novel indazole carboxamides and their use
TW200626142A (en)	2004-09-21	2006-08-01	Glaxo Group Ltd	Chemical compounds
NZ563687A (en) *	2005-06-30	2011-07-29	Smithkline Beecham Corp	3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta)
US8063071B2 (en)	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
EP1940296A2 (de) *	2005-10-25	2008-07-09	SmithKline Beecham Corporation	Chemische verbindungen
JP2009516702A (ja) *	2005-11-18	2009-04-23	スミスクライン・ビーチャム・コーポレイション	化合物
EP1959737A4 (de) *	2005-12-16	2010-12-08	Glaxosmithkline Llc	Chemische verbindungen
CN101583598B (zh) *	2007-01-15	2012-09-12	参天制药株式会社	具有IκB激酶β抑制活性的新型吲哚衍生物
AR065804A1 (es)	2007-03-23	2009-07-01	Smithkline Beecham Corp	Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
UA106037C2 (uk)	2008-02-04	2014-07-25	Мерк'Юрі Терап'Ютікс, Інк.	Модулятори ampk (амф-активованої протеїнкінази)
JPWO2009107391A1 (ja) *	2008-02-27	2011-06-30	武田薬品工業株式会社	６員芳香環含有化合物
JP2010043070A (ja) *	2008-07-14	2010-02-25	Santen Pharmaceut Co Ltd	カルバモイル基、ウレイド基及び置換オキシ基を有する新規インドール誘導体
EP2404897A4 (de) *	2009-03-05	2014-02-26	Sumitomo Chemical Co	Verfahren zur herstellung von halogensubstituiertem benzendimethanol
US8354539B2 (en)	2009-03-10	2013-01-15	Glaxo Group Limited	Indole derivatives as IKK2 inhibitors
EP2646020B1 (de) *	2010-12-01	2016-09-21	Glaxosmithkline LLC	Indole
WO2014036268A2 (en) *	2012-08-29	2014-03-06	Mount Sinai School Of Medicine	Indole derivatives as sumo activators
FR3001219A1 (fr) *	2013-01-22	2014-07-25	Centre Nat Rech Scient	Inhibiteurs de kinases
TWI644899B (zh)	2013-02-04	2018-12-21	健生藥品公司	Ｆｌａｐ調節劑
EP3495359A1 (de) *	2013-02-04	2019-06-12	Janssen Pharmaceutica NV	Flap-modulatoren
EP3483167A1 (de) *	2013-06-26	2019-05-15	AbbVie Inc.	Primäre carboxamide als btk-hemmer
EP3233835B1 (de) *	2014-12-18	2019-01-23	F.Hoffmann-La Roche Ag	Benzazepinsulfonamidverbindungen
US20170158702A1 (en) *	2015-12-02	2017-06-08	Kyras Therapeutics, Inc.	Multivalent ras binding compounds
US11352328B2 (en)	2016-07-12	2022-06-07	Arisan Therapeutics Inc.	Heterocyclic compounds for the treatment of arenavirus
JP7152479B2 (ja) *	2017-06-07	2022-10-12	中国中医科学院中▲薬▼研究所	インドール酢酸類誘導体、その製造方法及び医薬用途
US12419865B2 (en)	2018-12-06	2025-09-23	Arisan Therapeutics Inc.	Compounds for the treatment of arenavirus infection
WO2024059220A2 (en) *	2022-09-15	2024-03-21	Vanderbilt University	6,5 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
WO2026078446A2 (en) *	2024-10-08	2026-04-16	Brandaris Therapeutics B.V.	5,6-bicyclic 5-ht2ar agonists and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4775761A (en) *	1983-08-22	1988-10-04	Hoechst-Roussel Pharmaceuticals, Inc.	3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US5256673A (en) *	1983-11-25	1993-10-26	Merck Patent Gesellschaft Mit Beschrankter Haftung	Indole-3-yl-A-tetrahydropyridyl or piperidyl compounds
DE3342632A1 (de) *	1983-11-25	1985-06-05	Merck Patent Gmbh, 6100 Darmstadt	Indolderivate
JPH0262875A (ja) *	1988-05-23	1990-03-02	Wakunaga Pharmaceut Co Ltd	新規イソインドリン誘導体
US5254473A (en) *	1990-03-16	1993-10-19	Jp Laboratories	Solid state device for monitoring integral values of time and temperature of storage of perishables
US5330986A (en) *	1992-11-24	1994-07-19	Hoechst-Roussel Pharmaceuticals Inc.	Indole-7-carboxamide derivatives
ZA951822B (en) *	1994-12-23	1996-09-26	Glaxo Group Ltd	Chemical compounds
DE19756036A1 (de) *	1997-12-17	1999-06-24	Merck Patent Gmbh	Amid- und Harnstoffderivate
US6589954B1 (en) *	1998-05-22	2003-07-08	Scios, Inc.	Compounds and methods to treat cardiac failure and other disorders
AR025111A1 (es) *	1999-08-13	2002-11-06	Janus Pharmaceuticals Inc	Metodos y composiciones para tratar trastornos de ansiedad generalizada
US6245799B1 (en) *	1999-11-08	2001-06-12	American Home Products Corp	[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
WO2001081340A2 (en) *	2000-04-24	2001-11-01	Bristol-Myers Squibb Company	Heterocycles that are inhibitors of impdh enzyme
US6897231B2 (en) *	2000-07-31	2005-05-24	Signal Pharmaceuticals, Inc.	Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) *	2000-07-31	2005-01-13	Bhagwat Shripad S.	Indazole compounds, compositions thereof and methods of treatment therewith
CN1642973A (zh) *	2000-09-06	2005-07-20	奥索-麦克尼尔药品公司	治疗变态反应的方法
US6869956B2 (en) *	2000-10-03	2005-03-22	Bristol-Myers Squibb Company	Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
CN1503673A (zh) *	2000-10-26	2004-06-09	�㽭�пؼ��ɷ��޹�˾	消炎药
RU2294932C2 (ru) *	2001-06-07	2007-03-10	Ф.Хоффманн-Ля Рош Аг	Новые производные индола со сродством к рецептору 5-ht6
EP1444207A2 (de) *	2001-09-19	2004-08-11	Pharmacia Corporation	Substituierte pyrazolylverbindungen zur behandlung von entzündungen
AU2002356871A1 (en) *	2001-10-30	2003-05-12	Pharmacia Corporation	Heteroaromatic carboxamide derivatives for the treatment of inflammation
EP1495016A2 (de) *	2002-04-09	2005-01-12	Astex Technology Limited	Heterocyclische verbindungen und deren verwendung als p38 map kinase modulatoren
TW200403991A (en) *	2002-04-11	2004-03-16	Smithkline Beecham Corp	NF-κb inhibitors
JP4401298B2 (ja) *	2002-12-02	2010-01-20	エフ．ホフマン−ラロシュアーゲー	Ｃｒｆアンタゴニストとしてのインダゾール誘導体
WO2004053087A2 (en) *	2002-12-06	2004-06-24	Smithkline Beecham Corporation	Nf-κb inhibitors
US7572914B2 (en) *	2003-12-19	2009-08-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
DE102004012069A1 (de) *	2004-03-12	2005-09-29	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
TW200616967A (en) *	2004-06-24	2006-06-01	Smithkline Beecham Corp	Novel indazole carboxamides and their use
TW200626142A (en) *	2004-09-21	2006-08-01	Glaxo Group Ltd	Chemical compounds
ATE489138T1 (de) *	2005-04-13	2010-12-15	Neuraxon Inc	Substituierte indolverbindungen mit nos-hemmender aktivität
US8063071B2 (en) *	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
US7956082B2 (en) *	2005-07-22	2011-06-07	Shionogi & Co., Ltd	Indole derivative having PGD2 receptor antagonist activity
JP2009513677A (ja) *	2005-10-25	2009-04-02	スミスクライン・ビーチャム・コーポレイション	化合物
EP1940296A2 (de) *	2005-10-25	2008-07-09	SmithKline Beecham Corporation	Chemische verbindungen
JP2009516702A (ja) *	2005-11-18	2009-04-23	スミスクライン・ビーチャム・コーポレイション	化合物
EP1959737A4 (de) *	2005-12-16	2010-12-08	Glaxosmithkline Llc	Chemische verbindungen
US8008481B2 (en) *	2006-03-31	2011-08-30	Ericsson Anna M	Indazole compounds
US20100035917A1 (en) *	2006-09-22	2010-02-11	Paul Bamborough	Pyrrolo[2,3-b]pyridin-4-yl-benzenesulfonamide compounds as 1kk2 inhibitors
AR065804A1 (es) *	2007-03-23	2009-07-01	Smithkline Beecham Corp	Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
GB0710528D0 (en) *	2007-06-01	2007-07-11	Glaxo Group Ltd	Novel compounds

2004
- 2004-01-15 GB GBGB0400895.9A patent/GB0400895D0/en not_active Ceased
2005
- 2005-01-13 DK DK05701855T patent/DK1703905T3/da active
- 2005-01-13 DE DE602005010970T patent/DE602005010970D1/de not_active Expired - Lifetime
- 2005-01-13 WO PCT/GB2005/000085 patent/WO2005067923A1/en not_active Ceased
- 2005-01-13 KR KR1020067014178A patent/KR20070026357A/ko not_active Withdrawn
- 2005-01-13 PT PT05701855T patent/PT1703905E/pt unknown
- 2005-01-13 US US10/597,154 patent/US20080269200A1/en not_active Abandoned
- 2005-01-13 RU RU2006129492/04A patent/RU2006129492A/ru not_active Application Discontinuation
- 2005-01-13 BR BRPI0506802-9A patent/BRPI0506802A/pt not_active IP Right Cessation
- 2005-01-13 JP JP2006548393A patent/JP4975447B2/ja not_active Expired - Fee Related
- 2005-01-13 SI SI200530567T patent/SI1703905T1/sl unknown
- 2005-01-13 ES ES05701855T patent/ES2317184T3/es not_active Expired - Lifetime
- 2005-01-13 CA CA002552953A patent/CA2552953A1/en not_active Abandoned
- 2005-01-13 PL PL05701855T patent/PL1703905T3/pl unknown
- 2005-01-13 CN CNA2005800083624A patent/CN1933830A/zh active Pending
- 2005-01-13 AT AT05701855T patent/ATE413877T1/de not_active IP Right Cessation
- 2005-01-13 EP EP05701855A patent/EP1703905B1/de not_active Expired - Lifetime
- 2005-01-13 AU AU2005205090A patent/AU2005205090A1/en not_active Abandoned
- 2005-01-13 HR HR20090071T patent/HRP20090071T3/xx unknown
2006
- 2006-06-13 ZA ZA200604855A patent/ZA200604855B/xx unknown
- 2006-07-03 MA MA29154A patent/MA28279A1/fr unknown
- 2006-07-06 IL IL176739A patent/IL176739A0/en unknown
- 2006-08-15 NO NO20063676A patent/NO20063676L/no not_active Application Discontinuation
2011
- 2011-09-01 JP JP2011190903A patent/JP2012025761A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
PT1703905E (pt)	2009-02-04
PL1703905T3 (pl)	2009-04-30
DK1703905T3 (da)	2009-02-16
CN1933830A (zh)	2007-03-21
CA2552953A1 (en)	2005-07-28
DE602005010970D1 (de)	2008-12-24
EP1703905A1 (de)	2006-09-27
KR20070026357A (ko)	2007-03-08
EP1703905B1 (de)	2008-11-12
ATE413877T1 (de)	2008-11-15
RU2006129492A (ru)	2008-02-27
JP2007517848A (ja)	2007-07-05
US20080269200A1 (en)	2008-10-30
ES2317184T3 (es)	2009-04-16
MA28279A1 (fr)	2006-11-01
GB0400895D0 (en)	2004-02-18
JP4975447B2 (ja)	2012-07-11
WO2005067923A1 (en)	2005-07-28
SI1703905T1 (sl)	2009-04-30
HRP20090071T3 (en)	2009-04-30
IL176739A0 (en)	2006-10-31
JP2012025761A (ja)	2012-02-09
HK1098047A1 (en)	2007-07-13
ZA200604855B (en)	2007-11-28
BRPI0506802A (pt)	2007-05-29
AU2005205090A1 (en)	2005-07-28

Legal Events

Date	Code	Title	Description
2010-08-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
DK1703905T3 (da)	2009-02-16	Indol-derivater og anvendelse deraf som kinaseinhibitorer, især IKK2-inhibitorer
ECSP20027480A (es)	2020-06-30	Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
NO20071593L (no)	2007-05-22	Pyrimidinderivater
MY151455A (en)	2014-05-30	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NO20083427L (no)	2008-10-14	Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20082508L (no)	2008-07-31	Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20064976L (no)	2006-10-31	Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20072567L (no)	2007-07-17	Triazoler nyttige som proteinkinase-inhibitorer
NO20065727L (no)	2006-12-12	Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
MY147994A (en)	2013-02-28	Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
NO20081893L (no)	2008-05-20	4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20084435L (no)	2008-11-28	C-MET proteinkinaseinhibitorer
NO20071617L (no)	2007-04-20	Indozolonderivater som 11B-HSD1-inhibitorer
NO20081942L (no)	2008-04-23	Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20063925L (no)	2006-09-01	Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20076659L (no)	2008-03-18	Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20080141L (no)	2008-01-09	Indanderivater som modulatorer av ionekanaler
UY30500A1 (es)	2008-02-29	Compuestos de azabencimidazolilo
UA99617C2 (ru)	2012-09-10	Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
NO20084489L (no)	2008-12-19	Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20071137L (no)	2007-04-19	Nye piperidinderivater for behandling av depresjon
NO20091590L (no)	2009-05-08	Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
DK2207770T3 (da)	2011-09-12	1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
NI200900052A (es)	2010-02-01	Heterocíclicos derivados de los inhibidores de metaloproteasa